Rosenblatts’ Hans Mosesmann is especially upbeat on AMD’s new Ryzen models, in what he calls a record for the chip giant’s “most prolific new product ramp” to date.
Cowen’s Phil Nadeau sings the praises of this “undervalued” biotech stock, encouraged to see DVAX’s cancer drug SD-101 revealed well tolerated results in a mid-stage trial.
Oppenheimer’s Christopher Liu thinks the Street is too confident on SGYP ahead of its first earnings show of the year- opting for now to stick to the sidelines.
One top analyst sings Micron’s praises despite concerns of DRAM pricing weakness; another analyst lifts expectations on standout Intel fundamentals.
Oppenheimer’s Jason Helfstein has taken a close, confident look into BABA’s new retail and international pieces of the puzzle.
Though FANG name fears are running rampant through the Street, Daniel Ives remains a bull when it comes to bets on AMZN and FB.
Though Tim Long notes BlackBerry posted a robust fourth fiscal quarter for 2018, the guide hangs unclear for fiscal 2019 software revenue growth.